Review ArticlesCecropins Activity Against Bacterial PathogensGholizadeh, Abdolmajid PhD∗; Moradi, Bagher PhD†Author Information From the ∗Department of Environmental Health, School of Public Health, North Khorasan University of Medical Sciences, Bojnurd †Department of Basic Sciences, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran. Correspondence to: Bagher Moradi, PhD, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran. E-mail: [email protected]. The authors have no conflicts of interest to disclose. Infectious Diseases in Clinical Practice: January 2021 - Volume 29 - Issue 1 - p e6-e12 doi: 10.1097/IPC.0000000000000913 Buy Metrics Abstract Today, resistant bacteria are challenges in the treatment of bacterial infections. Cecropins are compounds that kill bacteria by affecting the membrane of microorganisms, such as Acinetobacter, Escherichia coli, and Staphylococcus. This study aimed to evaluate the antibacterial activity of cecropins against bacterial pathogens quantitatively. In this study, articles reporting antimicrobial activity of cecropins were searched in PubMed, Web of Science, and Scopus databases using the Google Scholar search engine. Then, the results of the current study were evaluated quantitatively. In this study, we found 29 studies reporting cecropins antimicrobial activity against major bacterial pathogens. Also, there were 25 studies on cecropin antimicrobial activity against gram-negative pathogens, and it was cleared that cecropin B antibacterial activity on Pseudomonas aeruginosa was lesser than others (minimum inhibitory concentration, 0.4 μg/ML), and we showed that Staphylococcus aureus growth can be inhibited by Cecropin AD more than others (minimum inhibitory concentration, 0.2 μg/Ml). Because cecropin peptides have no adverse effect on the human cells, and also, it has been demonstrated that cecropins have acceptable functions against pathogenic bacteria, we showed that they are potential candidates for research and construction of novel antibiotics. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.